Biotechnology stocks helped lead the market, and health care stocks in the S&P 500 rose 1.1 percent for one of the biggest gains of the 11 sectors that make up the index. Alexion Pharmaceuticals jumped $7.68, or 7.2 percent, to $114.46 for the biggest gain in the S&P 500 following a…
News
- S&P 500 returns to record following strong US jobs report
- Erytech Pharma Plummets on Phase 2 Data -- Biotech Movers
Shares rose 7.3% to $29.40 after the Waltham, Mass.-based firm on Thursday gave an update on data from the Phase 1 study of elacestrant (RAD1901) in patients with estrogen receptor positive (ER+) breast cancer. The data presentation took place at the 2017 San Antonio Breast Cancer Symposium.
- Blood Test May Help Predict Which Breast Cancers Will Recur
Sparano led the study and gave results Friday at the San Antonio Breast Cancer Symposium. The test—CellSearch, sold by Menarini-Silicon Biosystems—looks for stray cancer cells in the blood. Breast cancer survivors may be tempted to rush out and get it, but doctors say it's too soon for that.…
- Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio ...
NEW HAVEN, Conn., Dec. 8, 2017 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the presentation of new preclinical data for its novel oral estrogen receptor (ER) alpha PROTAC program…
- 3 Things In Biotech You Should Learn Today: December 8, 2017
News: NVS presented the findings from MONALEESA-7 at the San Antonio Breast Cancer Symposium, which explored the use of ribociclib (branded Kisqali) and endocrine therapy in premenopausal women with metastatic hormone-positive breast cancer. The findings were stellar, with a substantial…